Eosinophilic Gastritis Clinical Trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety,Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis
|Contact||Henrik Rasmussen, MD, PhD|
|Status||Not yet recruiting|
|Start date||April 2018|
|Completion date||September 2019|
This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses. It is hypothesized that AK002 is more effective than placebo control (alternative hypothesis) in reducing the number of eosinophils per high power field (HPF) in gastric and duodenal biopsies before and after receiving AK002 or placebo versus no difference between AK002 and placebo control (null hypothesis).
|Active, not recruiting||